Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Nov;66(11):1580-1585.
doi: 10.4103/ijo.IJO_427_18.

A prospective randomized controlled study of Aurolab aqueous drainage implant versus Ahmed glaucoma valve in refractory glaucoma: A pilot study

Shweta G Rathi  1 , Natasha G Seth  1 , Savleen Kaur  1 , Faisal Thattaruthody  1 , Sushmita Kaushik  1 , Srishti Raj  1 , Surinder S Pandav  1 , Jagat Ram  1
Affiliations
Randomized Controlled Trial

A prospective randomized controlled study of Aurolab aqueous drainage implant versus Ahmed glaucoma valve in refractory glaucoma: A pilot study

Shweta G Rathi et al. Indian J Ophthalmol. 2018 Nov.

Abstract

Purpose: To study the efficacy of the Aurolab aqueous drainage implant (AADI) compared to Ahmed glaucoma valve (AGV) in patients with refractory glaucoma.

Methods: This was a prospective, randomized controlled trial. Thirty-eight adult patients (>18 years) scheduled for a glaucoma drainage device (GDD) were randomized into two groups to receive either AGV or AADI. Primary outcome measures: intraocular pressure (IOP) control and requirement of antiglaucoma medications; secondary outcome measures: final best correct visual acuity (log MAR), visual field (Visual field index [VFI], mean deviation [MD] and pattern standard deviation [PSD]), postoperative complications and additional interventions. Complete success was defined as IOP ≥5-≤18 mmHg without antiglaucoma medications/laser/additional glaucoma surgery or any vision threatening complications.

Results: There were 19 age and sex-matched patients in each group. Both groups had comparable IOP before surgery (P = 0.61). The AGV group had significantly lower IOP compared to AADI group (7.05 ± 4.22 mmHg vs 17.90 ± 10.32 mmHg, P = <0.001) at 1 week. The mean postoperative IOP at 6 months was not significantly different in the two groups (13.3 ± 4.2 and 11.4 ± 6.8 mmHg respectively; P = 0.48). At 6 months, complete success rate according to antiglaucoma medication criteria was 78.94% in AADI and 47.36% in AGV groups. AGV group required 1.83 times more number of topical medications than AADI group. There was no significant difference in early (P = 0.75) and late (P = 0.71) postoperative complications in the AADI and AGV group. The complete success rate was higher in AADI group (68.42%) than AGV group (26.31%) (P = 0.034).

Conclusion: In this study, AADI appears to have comparable efficacy versus AGV implant with higher complete success rate at 6 months follow-up.

Keywords: Ahmed glaucoma valve; Aurolab aqueous drainage implant; refractory glaucoma.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest

Figures

Figure 1
Figure 1
IOP trends following AADI and AGV implantation
See this image and copyright information in PMC

Comment in

  • Commentary: AADI: New kid on the block.
    Pathak-Ray V. Pathak-Ray V. Indian J Ophthalmol. 2018 Nov;66(11):1585-1586. doi: 10.4103/ijo.IJO_1118_18. Indian J Ophthalmol. 2018. PMID: 30355866 Free PMC article. No abstract available.

References

    1. Ramulu PY, Corcoran KJ, Corcoran SL, Robbin Al. Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004. Ophthalmology. 2007;114:2265–70. - PubMed
    1. Desai MA, Gedde SJ, Feuer WJ, Shi W, Chen PP, Parrish RK., 2nd Practice preferences for glaucoma surgery: A survey of the American Glaucoma Society in 2008. Ophthalmic Surg Lasers Imaging. 2011;42:202–8. - PubMed
    1. Lloyd MA, Baerveldt G, Fellenbaum PS, Sidoti PA, Minckler DS, Martone JF, et al. Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm2 Baerveldt implant. Ophthalmology. 1994;101:1456–63. - PubMed
    1. Krishna R, Godfrey DG, Budenz DL, Escalona-Camaaño E, Gedde SJ, Greenfield DS, et al. Intermediate-term outcomes of 350-mm(2) Baerveldt glaucoma implants. Ophthalmology. 2001;108:621–6. - PubMed
    1. Kaushik S, Kataria P, Raj S, Pandav SS, Ram J. Safety and efficacy of low cost glaucoma drainage devices for refractory childhood glaucoma. Br J Ophthalmol. 2017;101:1623–27. - PubMed

Publication types